Post‐infectious irritable bowel syndrome (PI‐IBS) after infection with Shiga‐like toxin‐producing Escherichia coli (STEC) O104:H4: A cohort study with prospective follow‐up
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Background: In May/June 2011, the new Shiga‐like toxin‐producing Escherichia coli (STEC) strain O104:H4 caused the severest outbreak ever recorded of hemorrhagic enterocolitis in 3842 patients in Germany. Objectives: As bacterial enterocolitis is an established risk factor of subsequent irritable bowel syndrome (IBS), we aimed to estimate prevalence and incidence of post‐infectious (PI)‐IBS after six and 12 months in a cohort of STEC O104:H4 patients and to prospectively identify associated somatic and psychometric risk factors. Methods: A total of 389 patients were studied prospectively at baseline and at six and 12 months after STEC infection using STEC disease‐related questionnaires and validated instruments for IBS (Rome III) and psychological factors. Frequencies and logistic regression models using multiple imputations were applied to assess predictor variables. Results: Prevalence of IBS increased from 9.8% prior to STEC infection to 23.6% at six and 25.3% at 12 months after STEC infection. In patients without IBS symptoms prior to STEC infection, incidence of new IBS was 16.9%. Logistic regression models indicated higher somatization and anxiety scores as risk factors for, and mesalazine treatment during, STEC infection as the only significant protective factor against IBS. No other factor analyzed, including disease severity, showed an association. Conclusions: PI‐IBS rates following this unusually severe STEC outbreak were similar to what has been observed after other infectious gastroenteritis outbreaks. Our findings suggest that mesalazine may have reduced the risk of subsequent PI‐IBS. As altered mucosal immune activity is a pivotal pathogenic factor in PI‐IBS, our observation of a potential protective effect of mesalazine might be explained by its known modulatory action on mucosal immunity, and may warrant further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
Löwe, B., Decker, O., Müller, S., Brähler, E., Schellberg, D., Herzog, W., & Herzberg, P. Y. (2008) · Medical Care · doi:10.1097/mlr.0b013e318160d093 · Cited by 4,527
Self-citationEpidemic Profile of Shiga-Toxin–Producing Escherichia coli O104:H4 Outbreak in Germany
Frank, C., Werber, D., Cramer, J. P., Askar, M., Faber, M., an der Heiden, M., Bernard, H., Fruth, A., Prager, R., Spode, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106483 · Cited by 1,139 · cited 4×
“3%) of the patients developed hemolytic uremic syndrome (HUS) and overall, 53 patients died.(10,11) Thus, this was the most severe outbreak of E.”
BackgroundInfluentialIntestinal microbiota in functional bowel disorders: a Rome foundation report
Simrén, M., Barbara, G., Flint, H. J., Spiegel, B. M. R., Spiller, R. C., Vanner, S., Verdu, E. F., Whorwell, P. J., & Zoetendal, E. G. (2013) · Gut · doi:10.1136/gutjnl-2012-302167 · Cited by 939
Kocalevent, R.-D., Hinz, A., & Brähler, E. (2013) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2013.04.006 · Cited by 748
THABANE, M., KOTTACHCHI, D. T., & MARSHALL, J. K. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03399.x · Cited by 466
Postinfectious Irritable Bowel Syndrome-A Meta-Analysis
Halvorson, H. A., Schlett, C. D., & Riddle, M. S. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00654.x · Cited by 352
Buhner, S., Li, Q., Vignali, S., Barbara, G., De Giorgio, R., Stanghellini, V., Cremon, C., Zeller, F., Langer, R., Daniel, H., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.07.005 · Cited by 351
Jalanka-Tuovinen, J., Salojärvi, J., Salonen, A., Immonen, O., Garsed, K., Kelly, F. M., Zaitoun, A., Palva, A., Spiller, R. C., & de Vos, W. M. (2014) · Gut · doi:10.1136/gutjnl-2013-305994 · Cited by 340
Kocalevent, R.-D., Hinz, A., & Brähler, E. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-91 · Cited by 307 · cited 1×
“Regression analyses were performed based on the ‘‘forced entry’’ method, where all relevant variables are entered simultaneously based on their theoretical impact.(23) P values <0.”
Method
Cited by
Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome
Barbara, G., Grover, M., Bercik, P., Corsetti, M., Ghoshal, U. C., Ohman, L., & Rajilić-Stojanović, M. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.07.011 · Cited by 281
Donnachie, E., Schneider, A., Mehring, M., & Enck, P. (2018) · Gut · doi:10.1136/gutjnl-2017-313713 · Cited by 74
The development of irritable bowel syndrome: a prospective community-based cohort study
Löwe, B., Lohse, A., Andresen, V., Vettorazzi, E., Rose, M., & Broicher, W. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.255 · Cited by 43
Self-citation
Metadata
- Authors
- Andresen, V., Löwe, B., Broicher, W., Riegel, B., Fraedrich, K., von Wulffen, M., Gappmayer, K., Wegscheider, K., Treszl, A., Rose, M., Layer, P., & Lohse, A. W.
- Venue
- United European Gastroenterology Journal
- Publisher
- Wiley
- Published
- 2016-02
- Volume
- 4
- Issue
- 1
- Pages
- 121-131
- ISSN
- 2050-6406 (ISSN-L)
- 2050-6414
- OpenAlex
- W2029678437
- Cited by
- 38
- References
- 14
- FWCI
- 4.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Post‐infectious irritable bowel syndrome (PI‐IBS) after infection with Shiga‐like toxin‐producing Escherichia coli (STEC) O104:H4: A cohort study with prospective follow‐up. https://app.cochat.ai/papers/10.1177/2050640615581113
- The paper
- Andresen, V., Löwe, B., Broicher, W., Riegel, B., Fraedrich, K., von Wulffen, M., Gappmayer, K., Wegscheider, K., Treszl, A., Rose, M., Layer, P., & Lohse, A. W. (2016). Post‐infectious irritable bowel syndrome (PI‐IBS) after infection with Shiga‐like toxin‐producing Escherichia coli (STEC) O104:H4: A cohort study with prospective follow‐up. United European Gastroenterology Journal. https://doi.org/10.1177/2050640615581113
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.